Fabrication, design, and in vivo investigation of mesoporous silica-based docetaxel trihydrate nanoparticles for colonic drug delivery

Bulletin of the National Research Centre

Table 6 Comparison of pharmacokinetic data of docetaxel nanosuspension (formulation) and pure docetaxel powder (control) as microsuspension

Pharmacokinetic parameters	Pure docetaxel microsuspension (control)		Docetaxel nanosuspension (formulation)
C_max (ng/ml.)	Mean	98.03	Mean	213.67
C_max (ng/ml.)	± S.D	23.40	± S.D	72.21
t_max (min)	Mean	45.00	Mean	45.00
t_max (min)	± S.D	0.00	± S.D	0.00
AUC_0–t (ng. min/ml.)	Mean	9627.76	Mean	28,345.41
AUC_0–t (ng. min/ml.)	± S.D	2298.52	± S.D	9687.11
AUC_0–inf (ng. min/ml.)	Mean	9967.14	Mean	31,955.93
AUC_0–inf (ng. min/ml.)	± S.D	2386.35	± S.D	11,145.17
k_el (min⁻¹)	Mean	0.007	Mean	0.005
k_el (min⁻¹)	± S.D	0.000	± S.D	0.000
t_1/2 (min)	Mean	93.18	Mean	133.34
t_1/2 (min)	± S.D	3.47	± S.D	7.61